EF Hutton Initiates Coverage On ImmunityBio with Buy Rating, Announces Price Target of $30
Portfolio Pulse from Benzinga Newsdesk
EF Hutton has initiated coverage on ImmunityBio (NASDAQ:IBRX) with a Buy rating and set a price target of $30, indicating a positive outlook for the company's stock.
October 23, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton has initiated coverage on ImmunityBio with a Buy rating and a price target of $30, suggesting a positive short-term outlook for the stock.
The initiation of coverage with a Buy rating and a $30 price target by EF Hutton is likely to boost investor confidence and attract buying interest in ImmunityBio's stock, potentially driving the price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100